Association of factor expression levels with annual bleeding rate in people with haemophilia B
dc.contributor.author | Burke, Tom | |
dc.contributor.author | Shaikh, Anum | |
dc.contributor.author | Ali, Talaha M. | |
dc.contributor.author | Li, Nanxin | |
dc.contributor.author | Konkle, Barbara A. | |
dc.contributor.author | Noone, Declan | |
dc.contributor.author | O’Mahony, Brian | |
dc.contributor.author | Pipe, Steven | |
dc.contributor.author | O’Hara, Jamie | |
dc.date.accessioned | 2023-02-01T18:59:52Z | |
dc.date.available | 2024-02-01 13:59:50 | en |
dc.date.available | 2023-02-01T18:59:52Z | |
dc.date.issued | 2023-01 | |
dc.identifier.citation | Burke, Tom; Shaikh, Anum; Ali, Talaha M.; Li, Nanxin; Konkle, Barbara A.; Noone, Declan; O’Mahony, Brian; Pipe, Steven; O’Hara, Jamie (2023). "Association of factor expression levels with annual bleeding rate in people with haemophilia B." Haemophilia 29(1): 115-122. | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.issn | 1365-2516 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175799 | |
dc.description.abstract | IntroductionGene therapy clinical trials measure steady-state clotting factor expression levels (FELs) to evaluate the modulation of the bleeding phenotype, aiming to offer consistent protection against breakthrough bleeding events. The link between FELs and bleeding risk in people with haemophilia B (PwHB) is not well understood.AimWe evaluated the association between FEL and ABR in PwHB.MethodsThis cross-sectional study extended the CHESS burden of illness studies in Europe and the United States. Recruitment of additional adult males with haemophilia B supplemented the existing CHESS sample size of PwHB and FELs. PwHB receiving prophylaxis were excluded, as fluctuating FELs may have confounded the analysis. Demographic and clinical characteristics were reported descriptively. Any recorded baseline FEL was reported by the haemophilia-treating physicians according to the medical records. Generalised linear models with log link explored the association between changes in FEL and ABR.ResultsThe study included 407 PwHB and no inhibitors receiving on-demand treatment. Mean age was 36.7 years; 56% from the EU, 44% from the United States. Mean baseline FEL was 9.95 IU/dl (SD, 10.47); mean ABR was 2.4 bleeds/year (SD, 2.64). After adjusting for covariates, the model showed that for every 1% increase in FEL the average ABR decreased by .08 (p < .001). Predicted number of bleeding events according to FEL showed a significant non-linear relationship between FEL and ABR (p < .05).ConclusionThis analysis showed a significant relationship between FEL and ABR, where increases in FEL were associated with decreases in ABR among men with HB in Europe and the US. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | real-world data | |
dc.subject.other | haemophilia B | |
dc.subject.other | annual bleeding rate | |
dc.subject.other | factor expression level | |
dc.title | Association of factor expression levels with annual bleeding rate in people with haemophilia B | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175799/1/hae14675_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175799/2/hae14675.pdf | |
dc.identifier.doi | 10.1111/hae.14675 | |
dc.identifier.source | Haemophilia | |
dc.identifier.citedreference | O’Hara J, et al. Problem Joint” a more patient relevant definition for joint morbidity in haemophilia (P154) - Poster presentations. Haemophilia. 2019; 25: 35 - 188. | |
dc.identifier.citedreference | Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010; 29: 1037 - 1057. | |
dc.identifier.citedreference | Harrell FEJ, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988; 80: 1198 - 1202. | |
dc.identifier.citedreference | Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX- FP. J Med Econ. 2019; 22 ( 10 ): 1014 - 1021. | |
dc.identifier.citedreference | Iorio A, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA, US Hemophilia Treatment Center Network. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019; 171: 540 - 546. | |
dc.identifier.citedreference | Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12: 1935 - 1939. | |
dc.identifier.citedreference | Paroskie A, Gailani D, Debaun MR, Sidonio RF. A cross-sectional study of bleeding phenotype in haemophilia A carriers. Br J Haematol. 2015; 170: 223 - 228. | |
dc.identifier.citedreference | Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017; 23: 556 - 565. | |
dc.identifier.citedreference | Witkop ML, Lambing A, Nichols CD, Munn JE, Anderson TL, Tortella BJ. Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey. Patient Prefer Adherence. 2019; 13: 1577 - 1587. | |
dc.identifier.citedreference | O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual. Life Outcomes. 2018; 16: 84. | |
dc.identifier.citedreference | O’Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, Wilkinson L. The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rev. 2018; 8: 1 - 7. | |
dc.identifier.citedreference | Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus. 2013; 11: 178 - 182. | |
dc.identifier.citedreference | Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005; 1: 189 - 199. | |
dc.identifier.citedreference | Hermans C, Marino R, Lambert C. Real-World utilisation and bleed rates in patients with haemophilia B who switched to recombinant Factor IX Fusion Protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020; 37: 2988 - 2998. | |
dc.identifier.citedreference | Schrijvers LH, Beijlevelt-van der Zande M, Peters M, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016; 174: 454 - 460. | |
dc.identifier.citedreference | Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold? Blood Rev. 2018; 32: 52 - 60. | |
dc.identifier.citedreference | Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin North Am. 2017; 31: 853 - 868. | |
dc.identifier.citedreference | den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011; 17: 41 - 44. | |
dc.identifier.citedreference | Burke T, Asghar S, O’Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2020; 16: 521. | |
dc.identifier.citedreference | O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017; 12: 106. | |
dc.identifier.citedreference | Von Drygalski A, Giermasz A, Castama G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019; 3: 3241 - 3247. | |
dc.identifier.citedreference | Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011; 17: 849 - 853. | |
dc.identifier.citedreference | Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA, US Hemophilia Treatment Center Network. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018; 2: 2136 - 2144. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.